Trabectedin (BioDeep_00000011456)

   

human metabolite blood metabolite Marine Natural Products natural product


代谢物信息卡片


(1R,2R,3R,11S,12S,14R,26R)-5,6,12-trihydroxy-6,7-dimethoxy-7,21,30-trimethyl-27-oxo-3,4-dihydro-2H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1³,¹¹.0²,¹³.0⁴,⁹.0¹⁵,²³.0¹⁶,²⁰]triacontane-26,1-isoquinoline]-4,6,8,15,20,22-hexaen-22-yl acetate

化学式: C39H43N3O11S (761.2618)
中文名称: 曲贝替定
谱图信息: 最多检出来源 Homo sapiens(blood) 100%

分子结构信息

SMILES: CC1=CC2=C(C3C4C5C6=C(C(=C7C(=C6C(N4C(C(C2)N3C)O)COC(=O)C8(CS5)C9=CC(=C(C=C9CCN8)O)OC)OCO7)C)OC(=O)C)C(=C1OC)O
InChI: InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3

描述信息

Trabectedin, also referred as ET-743 during its development, is a marine derived antitumoral agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D009676 - Noxae > D000477 - Alkylating Agents
D000970 - Antineoplastic Agents

同义名列表

12 个代谢物同义名

(1R,2R,3R,11S,12S,14R,26R)-5,6,12-trihydroxy-6,7-dimethoxy-7,21,30-trimethyl-27-oxo-3,4-dihydro-2H-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1³,¹¹.0²,¹³.0⁴,⁹.0¹⁵,²³.0¹⁶,²⁰]triacontane-26,1-isoquinoline]-4,6,8,15,20,22-hexaen-22-yl acetate; ecteinascidin 743; Ecteinascidin; Yondelis (TN); Trabectedin; NSC 684766; Yondelis; CID 3199; Ect 743; ET-743; ET743; Trabectedin



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

10 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 10 ABCB1, ANG, BCL2, BRCA1, CYP3A4, ERBB2, ERCC1, EWSR1, TP53, VEGFA
Endosome membrane 1 ERBB2
Endoplasmic reticulum membrane 2 BCL2, CYP3A4
Nucleus 13 ANG, BCL2, BRCA1, BRCA2, CD274, ERBB2, ERCC1, ERCC5, EWSR1, HMGA2, PARP1, TP53, VEGFA
cytosol 7 ANG, BCL2, BRCA2, ERBB2, GPT, PARP1, TP53
nuclear body 2 BRCA1, PARP1
centrosome 2 BRCA2, TP53
nucleoplasm 10 BRCA1, BRCA2, CD274, ERBB2, ERCC1, ERCC5, EWSR1, HMGA2, PARP1, TP53
Cell membrane 6 ABCB1, CD274, CD8A, ERBB2, EWSR1, PDCD1
ruffle membrane 1 ERBB2
Early endosome membrane 1 CD274
Multi-pass membrane protein 1 ABCB1
cell surface 2 ABCB1, VEGFA
Golgi apparatus 1 VEGFA
growth cone 1 ANG
neuromuscular junction 1 ERBB2
neuronal cell body 1 ANG
presynaptic membrane 1 ERBB2
Cytoplasm, cytosol 1 PARP1
plasma membrane 7 ABCB1, BRCA1, CD274, CD8A, ERBB2, EWSR1, PDCD1
Membrane 11 ABCB1, BCL2, BRCA1, BRCA2, CYP3A4, ERBB2, ERCC5, PARP1, PDCD1, TP53, VEGFA
apical plasma membrane 2 ABCB1, ERBB2
basolateral plasma membrane 1 ERBB2
extracellular exosome 3 ABCB1, CD274, GPT
endoplasmic reticulum 3 BCL2, TP53, VEGFA
extracellular space 4 ANG, CSF3, IL6, VEGFA
lysosomal lumen 1 CSF3
perinuclear region of cytoplasm 1 ERBB2
adherens junction 1 VEGFA
mitochondrion 3 BCL2, PARP1, TP53
protein-containing complex 6 BCL2, BRCA1, BRCA2, ERCC5, PARP1, TP53
intracellular membrane-bounded organelle 1 CYP3A4
Microsome membrane 1 CYP3A4
Single-pass type I membrane protein 3 CD274, CD8A, ERBB2
Secreted 4 ANG, CSF3, IL6, VEGFA
extracellular region 6 ANG, CD8A, CSF3, ERBB2, IL6, VEGFA
Mitochondrion outer membrane 1 BCL2
Single-pass membrane protein 1 BCL2
mitochondrial outer membrane 1 BCL2
[Isoform 2]: Secreted 1 CD8A
Mitochondrion matrix 1 TP53
mitochondrial matrix 1 TP53
transcription regulator complex 2 PARP1, TP53
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome 2 BRCA2, TP53
Nucleus membrane 1 BCL2
Bcl-2 family protein complex 1 BCL2
nuclear membrane 1 BCL2
external side of plasma membrane 3 CD274, CD8A, PDCD1
Secreted, extracellular space, extracellular matrix 1 VEGFA
actin cytoskeleton 2 ANG, CD274
cytoplasmic vesicle 1 ERBB2
nucleolus 4 ANG, EWSR1, PARP1, TP53
Early endosome 1 ERBB2
Apical cell membrane 1 ABCB1
Cell projection, ruffle membrane 1 ERBB2
Cytoplasm, perinuclear region 1 ERBB2
pore complex 1 BCL2
Cytoplasm, cytoskeleton 1 TP53
extracellular matrix 1 VEGFA
basement membrane 1 ANG
Nucleus, PML body 1 TP53
PML body 1 TP53
secretory granule 2 BRCA2, VEGFA
receptor complex 2 CD8A, ERBB2
chromatin 3 HMGA2, PARP1, TP53
Chromosome 4 ANG, BRCA1, ERCC5, PARP1
[Isoform 3]: Nucleus 1 ERCC1
[Isoform 5]: Cytoplasm 1 BRCA1
Nucleus, nucleolus 2 ANG, PARP1
nuclear replication fork 1 PARP1
chromosome, telomeric region 3 BRCA2, ERCC1, PARP1
nuclear chromosome 1 HMGA2
site of double-strand break 2 PARP1, TP53
nuclear envelope 1 PARP1
Recycling endosome membrane 1 CD274
lateral element 2 BRCA1, BRCA2
Cytoplasm, Stress granule 1 ANG
cytoplasmic stress granule 1 ANG
germ cell nucleus 1 TP53
replication fork 1 TP53
myelin sheath 2 BCL2, ERBB2
ubiquitin ligase complex 1 BRCA1
basal plasma membrane 1 ERBB2
plasma membrane raft 1 CD8A
endoplasmic reticulum lumen 1 IL6
nuclear matrix 1 TP53
transcription repressor complex 1 TP53
male germ cell nucleus 1 BRCA1
platelet alpha granule lumen 1 VEGFA
XY body 1 BRCA1
endocytic vesicle 1 ANG
semaphorin receptor complex 1 ERBB2
[Isoform 2]: Cytoplasm 1 ERCC1
Cajal body 1 EWSR1
ribonucleoprotein complex 1 BRCA1
[Isoform 1]: Nucleus 2 ERCC1, TP53
SMAD protein complex 1 HMGA2
protein-DNA complex 2 HMGA2, PARP1
external side of apical plasma membrane 1 ABCB1
[Isoform 1]: Cell membrane 3 CD274, CD8A, ERBB2
[Isoform 4]: Secreted 1 CD274
intracellular non-membrane-bounded organelle 1 BRCA1
DNA repair complex 2 BRCA1, BRCA2
BRCA1-C complex 1 BRCA1
site of DNA damage 1 PARP1
[Isoform 4]: Nucleus 1 ERCC1
endocytic vesicle lumen 1 CSF3
T cell receptor complex 1 CD8A
angiogenin-PRI complex 1 ANG
ERBB3:ERBB2 complex 1 ERBB2
interleukin-6 receptor complex 1 IL6
ERCC4-ERCC1 complex 1 ERCC1
nucleotide-excision repair complex 2 ERCC1, ERCC5
nucleotide-excision repair factor 1 complex 1 ERCC1
[Poly [ADP-ribose] polymerase 1, processed N-terminus]: Chromosome 1 PARP1
[Poly [ADP-ribose] polymerase 1, processed C-terminus]: Cytoplasm 1 PARP1
BAD-BCL-2 complex 1 BCL2
[N-VEGF]: Cytoplasm 1 VEGFA
[VEGFA]: Secreted 1 VEGFA
[Isoform L-VEGF189]: Endoplasmic reticulum 1 VEGFA
[Isoform VEGF121]: Secreted 1 VEGFA
[Isoform VEGF165]: Secreted 1 VEGFA
VEGF-A complex 1 VEGFA
senescence-associated heterochromatin focus 1 HMGA2
BRCA1-A complex 1 BRCA1
BRCA1-B complex 1 BRCA1
BRCA1-BARD1 complex 1 BRCA1
gamma-tubulin ring complex 1 BRCA1
nuclear ubiquitin ligase complex 2 BRCA1, BRCA2
BRCA2-MAGE-D1 complex 1 BRCA2
[Isoform 2]: Endomembrane system 1 CD274


文献列表

  • Shunv Cai, Zewu Ding, Xinyi Liu, Jian Zeng. Trabectedin induces ferroptosis via regulation of HIF-1α/IRP1/TFR1 and Keap1/Nrf2/GPX4 axis in non-small cell lung cancer cells. Chemico-biological interactions. 2023 Jan; 369(?):110262. doi: 10.1016/j.cbi.2022.110262. [PMID: 36396105]
  • Emanuela Di Gregorio, Gianmaria Miolo, Agostino Steffan, Giuseppe Corona. Novel method for fast trabectedin quantification using hydrophilic interaction liquid chromatography and tandem mass spectrometry for human pharmacokinetic studies. Journal of pharmaceutical and biomedical analysis. 2020 Jun; 185(?):113261. doi: 10.1016/j.jpba.2020.113261. [PMID: 32229403]
  • Italo Poggesi, Belén Valenzuela, Daniele Ouellet, Martha Gonzalez, Vera Hillewaert, Sylvain Baruchel, Elizabeth Fox, Juan Jose Perez-Ruixo. Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer chemotherapy and pharmacology. 2019 10; 84(4):707-717. doi: 10.1007/s00280-019-03899-y. [PMID: 31286189]
  • Rizwan Ishtiaq, Arslan Naeem, Iqbal Ratnani. Thoracic Liposarcoma In An End Stage Renal Disease Patient. Journal of Ayub Medical College, Abbottabad : JAMC. 2019 Apr; 31(2):286-289. doi: NULL. [PMID: 31094134]
  • Maria Cucè, Maria Eugenia Gallo Cantafio, Maria Anna Siciliano, Caterina Riillo, Daniele Caracciolo, Francesca Scionti, Nicoletta Staropoli, Valeria Zuccalà, Lorenza Maltese, Anna Di Vito, Katia Grillone, Vito Barbieri, Mariamena Arbitrio, Maria Teresa Di Martino, Marco Rossi, Nicola Amodio, Pierosandro Tagliaferri, Pierfrancesco Tassone, Cirino Botta. Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. Journal of hematology & oncology. 2019 03; 12(1):32. doi: 10.1186/s13045-019-0714-9. [PMID: 30898137]
  • Toru Ishiguro, Yu Muta, Tetsuya Ito, Noriyasu Chika, Satoshi Hatano, Kunihiko Amano, Shunsuke Muramatsu, Okihide Suzuki, Yoshitaka Toyomasu, Minoru Fukuchi, Youichi Kumagai, Keiichiro Ishibashi, Erito Mochiki, Hideyuki Ishida. [A Case of Giant Retroperitoneal Liposarcoma Resected after Trabectedin Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2018 Dec; 45(13):2132-2134. doi: NULL. [PMID: 30692308]
  • Emiliano Calvo, Analia Azaro, Jordi Rodon, Luc Dirix, Manon Huizing, Francis Mark Senecal, Patricia LoRusso, Lorrin Yee, Italo Poggesi, Jan de Jong, Spyros Triantos, Youn C Park, Roland E Knoblauch, Trilok V Parekh, George D Demetri, Margaret von Mehren. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Investigational new drugs. 2018 06; 36(3):476-486. doi: 10.1007/s10637-017-0546-9. [PMID: 29177975]
  • E Erba, M Romano, M Gobbi, M Zucchetti, M Ferrari, C Matteo, N Panini, B Colmegna, G Caratti, L Porcu, R Fruscio, M V Perlangeli, D Mezzanzanica, D Lorusso, F Raspagliesi, M D'Incalci. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. Biochemical pharmacology. 2017 11; 144(?):52-62. doi: 10.1016/j.bcp.2017.08.001. [PMID: 28782526]
  • S Stacchiotti, M Saponara, R Frapolli, M Tortoreto, D Cominetti, S Provenzano, T Negri, G P Dagrada, A Gronchi, C Colombo, B Vincenzi, G Badalamenti, V Zuco, S L Renne, P Collini, C Morosi, A P Dei Tos, E Bello, S Pilotti, P G Casali, M D'Incalci, N Zaffaroni. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European journal of cancer (Oxford, England : 1990). 2017 05; 76(?):84-92. doi: 10.1016/j.ejca.2017.02.002. [PMID: 28284173]
  • David J Newman. Developing natural product drugs: Supply problems and how they have been overcome. Pharmacology & therapeutics. 2016 06; 162(?):1-9. doi: 10.1016/j.pharmthera.2015.12.002. [PMID: 26706239]
  • Margaret von Mehren, Michael Bookman, Neal J Meropol, Louis M Weiner, Eric Sherman, Jinhui Li, Roland Knoblauch, Trilok Parekh, Roger B Cohen. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer chemotherapy and pharmacology. 2015 May; 75(5):1047-55. doi: 10.1007/s00280-015-2705-z. [PMID: 25791363]
  • Takafumi Ueda, Shigeki Kakunaga, Masashi Ando, Kan Yonemori, Hideshi Sugiura, Kenji Yamada, Akira Kawai. Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma. Investigational new drugs. 2014 Aug; 32(4):691-9. doi: 10.1007/s10637-014-0094-5. [PMID: 24696229]
  • Monique Zangarini, Laura Ceriani, Federica Sala, Elena Marangon, Renzo Bagnati, Maurizio D'Incalci, Federica Grosso, Massimo Zucchetti. Quantification of trabectedin in human plasma: validation of a high-performance liquid chromatography-mass spectrometry method and its application in a clinical pharmacokinetic study. Journal of pharmaceutical and biomedical analysis. 2014 Jul; 95(?):107-12. doi: 10.1016/j.jpba.2014.02.018. [PMID: 24662672]
  • Francesca Bruder, Daniela Massa, Michela Barca, Viviana Contu, Mario Airoldi, Alice Crova. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma. Tumori. 2014 May; 100(3):e63-6. doi: 10.1700/1578.17230. [PMID: 25076252]
  • Cristiana Sessa, Gianluca Del Conte, Alexandre Christinat, Sara Cresta, Antonella Perotti, Elisa Gallerani, Pilar Lardelli, Carmen Kahatt, Vicente Alfaro, Jorge L Iglesias, Carlos Fernández-Teruel, Luca Gianni. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Investigational new drugs. 2013 Oct; 31(5):1236-43. doi: 10.1007/s10637-013-9942-y. [PMID: 23467812]
  • Sabino Strippoli, Vito Lorusso, Anna Albano, Michele Guida. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC complementary and alternative medicine. 2013 Jul; 13(?):199. doi: 10.1186/1472-6882-13-199. [PMID: 23899130]
  • Maung Maung Myat Moe, Carlos Fernandez Teruel, Arturo Soto-Matos. Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failure. Chemotherapy. 2013; 59(6):458-60. doi: 10.1159/000365071. [PMID: 25171649]
  • Meredith K Chuk, Alberta Aikin, Trish Whitcomb, Brigitte C Widemann, Peter Zannikos, Eliel Bayever, Frank M Balis, Elizabeth Fox. A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors. Pediatric blood & cancer. 2012 Nov; 59(5):865-9. doi: 10.1002/pbc.24201. [PMID: 22847981]
  • Juliette Thariat, Marie-Christine Etienne-Grimaldi, Vincent Launay-Vacher, Arturo Soto-Matos, Carlos Fernandez-Teruel, Thomas Ghafari, Pierre-Yves Marcy, Gérard Milano, Nicole Renée, Lauris Gastaud, Antoine Thyss. Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease. Cancer chemotherapy and pharmacology. 2011 Nov; 68(5):1363-7. doi: 10.1007/s00280-011-1718-5. [PMID: 21850465]
  • Jordi Martínez-Serra, Elena Maffiotte, Javier Martín, Teresa Bex, María Navarro-Palou, Teresa Ros, Joana M Plazas, Oliver Vögler, Antonio Gutiérrez, Juan Carlos Amat, Rafael Ramos, Carlos Saus, Jordi Ginés, Regina Alemany, Matias Diaz, Joan Besalduch. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. European journal of pharmacology. 2011 May; 658(2-3):57-64. doi: 10.1016/j.ejphar.2011.02.035. [PMID: 21371453]
  • Amy M Pick, Kelly K Nystrom. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2010 Dec; 16(4):269-72. doi: 10.1177/1078155209352821. [PMID: 20015930]
  • J H Beumer, N E Franke, R Tolboom, T Buckle, H Rosing, L Lopez-Lazaro, J H M Schellens, J H Beijnen, O van Tellingen. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Investigational new drugs. 2010 Apr; 28(2):145-55. doi: 10.1007/s10637-009-9234-8. [PMID: 19238326]
  • C Sessa, S Cresta, C Noberasco, G Capri, E Gallerani, F De Braud, M Zucchetti, M D'Incalci, A Locatelli, S Marsoni, I Corradino, C Minoia, P Zintl, L Gianni. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. European journal of cancer (Oxford, England : 1990). 2009 Aug; 45(12):2116-22. doi: 10.1016/j.ejca.2009.04.002. [PMID: 19419856]
  • Jan Handrick Beumer, L Lopez-Lazaro, Jan H M Schellens, Jos H Beijnen, Olaf van Tellingen. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Current clinical pharmacology. 2009 Jan; 4(1):38-42. doi: 10.2174/157488409787236047. [PMID: 19149499]
  • Wells A Messersmith, Antonio Jimeno, David Ettinger, Dan Laheru, Julie Brahmer, Dina Lansey, Yasmin Khan, Ross C Donehower, Yusri Elsayed, Peter Zannikos, Manuel Hidalgo. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2008 Dec; 63(1):181-8. doi: 10.1007/s00280-008-0733-7. [PMID: 18379785]
  • M von Mehren, R J Schilder, J D Cheng, E Temmer, T M Cardoso, F G Renshaw, E Bayever, P Zannikos, Z Yuan, R B Cohen. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Oct; 19(10):1802-9. doi: 10.1093/annonc/mdn363. [PMID: 18497430]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Gerald J Fetterly, Joel S Owen, Kim Stuyckens, Julie A Passarell, Peter Zannikos, Arturo Soto-Matos, Miguel Angel Izquierdo, Juan Jose Perez-Ruixo. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer chemotherapy and pharmacology. 2008 Jun; 62(1):135-47. doi: 10.1007/s00280-007-0583-8. [PMID: 17922277]
  • Jan H Beumer, Jeany M Rademaker-Lakhai, Hilde Rosing, Michel J X Hillebrand, Tessa M Bosch, Luis Lopez-Lazaro, Jan H M Schellens, Jos H Beijnen. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer chemotherapy and pharmacology. 2007 May; 59(6):825-37. doi: 10.1007/s00280-006-0342-2. [PMID: 16988825]
  • Jan-Hendrik Beumer, Tessa Buckle, Mariet Ouwehand, Niels E F Franke, Luis Lopez-Lazaro, Jan H M Schellens, Jos H Beijnen, Olaf van Tellingen. Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype. Investigational new drugs. 2007 Feb; 25(1):1-7. doi: 10.1007/s10637-006-7773-9. [PMID: 16633714]
  • Juan Jose Perez-Ruixo, Peter Zannikos, Sarapee Hirankarn, Kim Stuyckens, Elizabeth A Ludwig, Arturo Soto-Matos, Luis Lopez-Lazaro, Joel S Owen. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clinical pharmacokinetics. 2007; 46(10):867-84. doi: 10.2165/00003088-200746100-00005. [PMID: 17854236]
  • Thomas Manning, Emily Rhodes, Richard Loftis, Dennis Phillips, Don Demaria, David Newman, Jack Rudloe. ET743: Chemical analysis of the sea squirt Ecteinascidia turbinata ecosystem. Natural product research. 2006 May; 20(5):461-73. doi: 10.1080/14786410500462462. [PMID: 16644544]
  • J H Beumer, J M Rademaker-Lakhai, H Rosing, L Lopez-Lazaro, J H Beijnen, J H M Schellens. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Investigational new drugs. 2005 Oct; 23(5):429-36. doi: 10.1007/s10637-005-2902-4. [PMID: 16133794]
  • J H Beumer, J H M Schellens, J H Beijnen. Hepatotoxicity and metabolism of trabectedin: a literature review. Pharmacological research. 2005 May; 51(5):391-8. doi: 10.1016/j.phrs.2004.12.001. [PMID: 15749453]
  • Sarah Donald, Richard D Verschoyle, Peter Greaves, Tina Colombo, Massimo Zucchetti, Cristiano Falcioni, Marco Zaffaroni, Maurizio D'Incalci, Margaret M Manson, Jose Jimeno, William P Steward, Andreas J Gescher. Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma. International journal of cancer. 2004 Oct; 111(6):961-7. doi: 10.1002/ijc.20356. [PMID: 15300810]
  • R Garcia-Carbonero, J G Supko, J Manola, M V Seiden, D Harmon, D P Ryan, M T Quigley, P Merriam, J Canniff, G Goss, U Matulonis, R G Maki, T Lopez, T A Puchalski, M A Sancho, J Gomez, C Guzman, J Jimeno, G D Demetri. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Apr; 22(8):1480-90. doi: 10.1200/jco.2004.02.098. [PMID: 15084621]
  • E Stokvis, H Rosing, L López-Lázaro, J H Beijnen. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. Journal of mass spectrometry : JMS. 2004 Apr; 39(4):431-6. doi: 10.1002/jms.608. [PMID: 15103657]
  • Sarah Donald, Richard D Verschoyle, Peter Greaves, Samantha Orr, Jose Jimeno, Andreas J Gescher. Comparison of four modulators of drug metabolism as protectants against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the female rat and in hepatocytes in vitro. Cancer chemotherapy and pharmacology. 2004 Apr; 53(4):305-12. doi: 10.1007/s00280-003-0744-3. [PMID: 14669039]
  • Gianluca Tognon, Roberta Frapolli, Marco Zaffaroni, Eugenio Erba, Massimo Zucchetti, Glynn T Faircloth, Maurizio D'Incalci. Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies. Cancer chemotherapy and pharmacology. 2004 Jan; 53(1):89-90. doi: 10.1007/s00280-003-0704-y. [PMID: 14586558]
  • Li Shao, Jeremy Kasanov, Francis J Hornicek, Takeshi Morii, Gertrude Fondren, Lawrence Weissbach. Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations. Biochemical pharmacology. 2003 Dec; 66(12):2381-95. doi: 10.1016/j.bcp.2003.08.033. [PMID: 14637196]
  • Sarah Donald, Richard D Verschoyle, Peter Greaves, Timothy W Gant, Tina Colombo, Marco Zaffaroni, Roberta Frapolli, Massimo Zucchetti, Maurizio D'Incalci, Daniela Meco, Riccardo Riccardi, Luis Lopez-Lazaro, Jose Jimeno, Andreas J Gescher. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer research. 2003 Sep; 63(18):5902-8. doi: NULL. [PMID: 14522916]
  • C Twelves, K Hoekman, A Bowman, J B Vermorken, A Anthoney, J Smyth, C van Kesteren, J H Beijnen, J Uiters, J Wanders, J Gomez, C Guzmán, J Jimeno, A Hanauske. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. European journal of cancer (Oxford, England : 1990). 2003 Sep; 39(13):1842-51. doi: 10.1016/s0959-8049(03)00458-1. [PMID: 12932661]
  • Daniela Meco, Tina Colombo, Paolo Ubezio, Massimo Zucchetti, Marco Zaffaroni, Anna Riccardi, Glynn Faircloth, Jimeno Jose, Maurizio D'Incalci, Riccardo Riccardi. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer chemotherapy and pharmacology. 2003 Aug; 52(2):131-8. doi: 10.1007/s00280-003-0636-6. [PMID: 12783202]
  • Virginie Poindessous, Florence Koeppel, Eric Raymond, Martine Comisso, Stephen J Waters, Annette K Larsen. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Jul; 9(7):2817-25. doi: ". [PMID: 12855662]
  • Thomas A Puchalski, David P Ryan, Rocio Garcia-Carbonero, George D Demetri, Leah Butkiewicz, David Harmon, Michael V Seiden, Robert G Maki, Luis Lopez-Lazaro, Jose Jimeno, Cecilia Guzman, Jeffrey G Supko. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer chemotherapy and pharmacology. 2002 Oct; 50(4):309-19. doi: 10.1007/s00280-002-0498-3. [PMID: 12357306]
  • Joel M Reid, Mary J Kuffel, Stacie L Ruben, Jose J Morales, Kenneth L Rinehart, David P Squillace, Matthew M Ames. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Sep; 8(9):2952-62. doi: . [PMID: 12231541]
  • Sarah Donald, Richard D Verschoyle, Richard Edwards, David J Judah, Reginald Davies, Joan Riley, David Dinsdale, Luis Lopez Lazaro, Andrew G Smith, Timothy W Gant, Peter Greaves, Andreas J Gescher. Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat. Cancer research. 2002 Aug; 62(15):4256-62. doi: NULL. [PMID: 12154027]
  • Charlotte van Kesteren, Chris Twelves, Angela Bowman, Klaas Hoekman, Luis López-Lázaro, José Jimeno, Cecilia Guzman, Ron A A Mathôt, Andrew Simpson, Jan B Vermorken, John Smyth, Jan H M Schellens, Michel J X Hillebrand, Hilde Rosing, Jos H Beijnen. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anti-cancer drugs. 2002 Apr; 13(4):381-93. doi: 10.1097/00001813-200204000-00007. [PMID: 11984084]
  • Miguel A Villalona-Calero, S Gail Eckhardt, Geoffrey Weiss, Manuel Hidalgo, Jos H Beijnen, Charlotte van Kesteren, Hilde Rosing, Elizabeth Campbell, Maura Kraynak, Luis Lopez-Lazaro, Cecilia Guzman, Daniel D Von Hoff, Jose Jimeno, Eric K Rowinsky. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Jan; 8(1):75-85. doi: NULL. [PMID: 11801542]
  • David P Ryan, Thomas Puchalski, Jeffrey G Supko, David Harmon, Robert Maki, Rocio Garcia-Carbonero, Caroline Kuhlman, Jennifer Winkelman, Priscilla Merriam, Travis Quigley, Jose Jimeno, Judith Manola, George D Demetri. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. The oncologist. 2002; 7(6):531-8. doi: 10.1634/theoncologist.7-6-531. [PMID: 12490740]
  • C van Kesteren, R A Mathĵt, L López-Lázaro, E Cvitkovic, A Taamma, J M Jimeno, C Guzman, J H Schellens, J L Misset, E Brain, M J Hillebrand, H Rosing, J H Beijnen. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer chemotherapy and pharmacology. 2001 Dec; 48(6):459-66. doi: 10.1007/s002800100368. [PMID: 11800026]
  • R W Sparidans, H Rosing, M J Hillebrand, L López-Lázaro, J M Jimeno, I Manzanares, C van Kesteren, E Cvitkovic, A T van Oosterom, J H Schellens, J H Beijnen. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man. Anti-cancer drugs. 2001 Sep; 12(8):653-66. doi: 10.1097/00001813-200109000-00003. [PMID: 11604552]
  • D P Ryan, J G Supko, J P Eder, M V Seiden, G Demetri, T J Lynch, A J Fischman, J Davis, J Jimeno, J W Clark. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Feb; 7(2):231-42. doi: . [PMID: 11234874]
  • C van Kesteren, E Cvitkovic, A Taamma, L López-Lázaro, J M Jimeno, C Guzman, R A Math t, J H Schellens, J L Misset, E Brain, M J Hillebrand, H Rosing, J H Beijnen. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Dec; 6(12):4725-32. doi: . [PMID: 11156226]
  • H Rosing, M J Hillebrand, J M Jimeno, A Gómez, P Floriano, G Faircloth, R E Henrar, J B Vermorken, E Cvitkovic, A Bult, J H Beijnen. Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of mass spectrometry : JMS. 1998 Nov; 33(11):1134-40. doi: 10.1002/(sici)1096-9888(1998110)33:11<1134::aid-jms730>3.0.co;2-s. [PMID: 9835068]
  • E Izbicka, R Lawrence, E Raymond, G Eckhardt, G Faircloth, J Jimeno, G Clark, D D Von Hoff. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Annals of oncology : official journal of the European Society for Medical Oncology. 1998 Sep; 9(9):981-7. doi: 10.1023/a:1008224322396. [PMID: 9818072]
  • H Rosing, M J Hillebrand, J M Jimeno, A Gómez, P Floriano, G Faircloth, L Cameron, R E Henrar, J B Vermorken, A Bult, J H Beijnen. Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction. Journal of chromatography. B, Biomedical sciences and applications. 1998 Jun; 710(1-2):183-9. doi: 10.1016/s0378-4347(98)00143-1. [PMID: 9686886]
  • J Watkins, A Padfield, J D Alderson. Underlying immunopathology as a cause of adverse responses to two intravenous anaesthetic agents. British medical journal. 1978 May; 1(6121):1180-1. doi: 10.1136/bmj.1.6121.1180. [PMID: 638678]
  • T Fukushima. [Monoamine oxidase (XXXVI). Characteristics of benzylamine oxidase in the dog serum]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 1975 Jul; 71(5):457-62. doi: . [PMID: 280]